| pubmed-article:19928413 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19928413 | lifeskim:mentions | umls-concept:C0138741 | lld:lifeskim |
| pubmed-article:19928413 | lifeskim:mentions | umls-concept:C0033572 | lld:lifeskim |
| pubmed-article:19928413 | lifeskim:mentions | umls-concept:C0005558 | lld:lifeskim |
| pubmed-article:19928413 | lifeskim:mentions | umls-concept:C1514721 | lld:lifeskim |
| pubmed-article:19928413 | lifeskim:mentions | umls-concept:C0178587 | lld:lifeskim |
| pubmed-article:19928413 | lifeskim:mentions | umls-concept:C0439275 | lld:lifeskim |
| pubmed-article:19928413 | lifeskim:mentions | umls-concept:C1552861 | lld:lifeskim |
| pubmed-article:19928413 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19928413 | pubmed:dateCreated | 2009-11-24 | lld:pubmed |
| pubmed-article:19928413 | pubmed:abstractText | Elevated level of prostatic specific antigen (PSA) is an established parameter to help determine the need to perform prostate biopsy. The aim of the present study was to determine whether PSA density (PSAD) could better predict pathologic finding of 12-core prostate biopsy in men with PSA 4-10 ng/mL than PSA alone. Transrectal ultrasound guided biopsy was performed in 125 men with PSA within this range. The rate of cancer detection was 24%. Study results showed a significant difference in PSAD between the two patient groups with negative and positive biopsy findings (P=0.002), while difference in the measured PSA levels was not significant (P=0.091). Study results suggested that PSAD could serve as an additional parameter in predicting negative outcome of prostate biopsy, with a cut-off value of 0.15 ng/mL/mL within PSA range of 4-10 ng/mL (sensitivity 86.7% and negative predictive value 91.5%). | lld:pubmed |
| pubmed-article:19928413 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19928413 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19928413 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19928413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19928413 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19928413 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19928413 | pubmed:issn | 0353-9466 | lld:pubmed |
| pubmed-article:19928413 | pubmed:author | pubmed-author:SinaniM BMB | lld:pubmed |
| pubmed-article:19928413 | pubmed:author | pubmed-author:BenkoGoranG | lld:pubmed |
| pubmed-article:19928413 | pubmed:author | pubmed-author:LodetaBranimi... | lld:pubmed |
| pubmed-article:19928413 | pubmed:author | pubmed-author:FilipanZoranZ | lld:pubmed |
| pubmed-article:19928413 | pubmed:author | pubmed-author:StajcarDamirD | lld:pubmed |
| pubmed-article:19928413 | pubmed:author | pubmed-author:Dujmovi?Ton?i... | lld:pubmed |
| pubmed-article:19928413 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19928413 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:19928413 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19928413 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19928413 | pubmed:pagination | 153-5 | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:meshHeading | pubmed-meshheading:19928413... | lld:pubmed |
| pubmed-article:19928413 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19928413 | pubmed:articleTitle | Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4-10 ng/ml. | lld:pubmed |
| pubmed-article:19928413 | pubmed:affiliation | Department of Urology, Varazdin General Hospital, Varazdin, Croatia. blodeta@hotmail.com | lld:pubmed |
| pubmed-article:19928413 | pubmed:publicationType | Journal Article | lld:pubmed |
